Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.

Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, Al-Awar R, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD.

Cancer Cell. 2015 Jun 8;27(6):864-76. doi: 10.1016/j.ccell.2015.05.004.

PMID:
26058080
2.

Global analysis of fungal morphology exposes mechanisms of host cell escape.

O'Meara TR, Veri AO, Ketela T, Jiang B, Roemer T, Cowen LE.

Nat Commun. 2015 Mar 31;6:6741. doi: 10.1038/ncomms7741.

3.

Differential regulation of FGFR3 by PTPN1 and PTPN2.

St-Germain JR, Taylor P, Zhang W, Li Z, Ketela T, Moffat J, Neel BG, Trudel S, Moran MF.

Proteomics. 2015 Jan;15(2-3):419-33. doi: 10.1002/pmic.201400259. Epub 2014 Dec 17.

PMID:
25311528
4.

The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1.

Cullis J, Meiri D, Sandi MJ, Radulovich N, Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, Marshall CB, Ikura M, Ketela T, Moffat J, Neel BG, Gingras AC, Tsao MS, Rottapel R.

Cancer Cell. 2014 Feb 10;25(2):181-95. doi: 10.1016/j.ccr.2014.01.025.

5.

shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer.

Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, Ketela T, Jiang Z, Schachter NF, Rottapel R, Egan SE, Al-Awar R, Moffat J, Zacksenhaus E.

Cancer Res. 2014 Apr 1;74(7):2119-30. doi: 10.1158/0008-5472.CAN-13-2138. Epub 2014 Jan 31.

6.

A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.

Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J.

Mol Syst Biol. 2013 Oct 8;9:696. doi: 10.1038/msb.2013.54.

7.

Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fate.

Findlay GM, Smith MJ, Lanner F, Hsiung MS, Gish GD, Petsalaki E, Cockburn K, Kaneko T, Huang H, Bagshaw RD, Ketela T, Tucholska M, Taylor L, Bowtell DD, Moffat J, Ikura M, Li SS, Sidhu SS, Rossant J, Pawson T.

Cell. 2013 Feb 28;152(5):1008-20. doi: 10.1016/j.cell.2013.01.056.

8.

Suppression of cancer progression by MGAT1 shRNA knockdown.

Beheshti Zavareh R, Sukhai MA, Hurren R, Gronda M, Wang X, Simpson CD, Maclean N, Zih F, Ketela T, Swallow CJ, Moffat J, Rose DR, Schachter H, Schimmer AD, Dennis JW.

PLoS One. 2012;7(9):e43721. doi: 10.1371/journal.pone.0043721. Epub 2012 Sep 5.

9.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JL, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J.

Cancer Discov. 2012 Feb;2(2):172-89. doi: 10.1158/2159-8290.CD-11-0224. Epub 2011 Dec 29.

10.

A genome wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance.

Simpson CD, Hurren R, Kasimer D, MacLean N, Eberhard Y, Ketela T, Moffat J, Schimmer AD.

Apoptosis. 2012 Jul;17(7):666-78. doi: 10.1007/s10495-012-0723-4.

PMID:
22488300
11.

Analysis of early C2C12 myogenesis identifies stably and differentially expressed transcriptional regulators whose knock-down inhibits myoblast differentiation.

Rajan S, Chu Pham Dang H, Djambazian H, Zuzan H, Fedyshyn Y, Ketela T, Moffat J, Hudson TJ, Sladek R.

Physiol Genomics. 2012 Feb 1;44(2):183-97. doi: 10.1152/physiolgenomics.00093.2011. Epub 2011 Dec 6.

12.

COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines.

Koh JL, Brown KR, Sayad A, Kasimer D, Ketela T, Moffat J.

Nucleic Acids Res. 2012 Jan;40(Database issue):D957-63. doi: 10.1093/nar/gkr959. Epub 2011 Nov 18.

13.

Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD.

Cancer Cell. 2011 Nov 15;20(5):674-88. doi: 10.1016/j.ccr.2011.10.015.

14.

CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.

Mak AB, Blakely KM, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T, Moffat J.

J Biol Chem. 2011 Nov 25;286(47):41046-56. doi: 10.1074/jbc.M111.261545. Epub 2011 Sep 21.

15.

Pooled lentiviral shRNA screening for functional genomics in mammalian cells.

Blakely K, Ketela T, Moffat J.

Methods Mol Biol. 2011;781:161-82. doi: 10.1007/978-1-61779-276-2_9.

PMID:
21877282
16.

A comprehensive platform for highly multiplexed mammalian functional genetic screens.

Ketela T, Heisler LE, Brown KR, Ammar R, Kasimer D, Surendra A, Ericson E, Blakely K, Karamboulas D, Smith AM, Durbic T, Arnoldo A, Cheung-Ong K, Koh JL, Gopal S, Cowley GS, Yang X, Grenier JK, Giaever G, Root DE, Moffat J, Nislow C.

BMC Genomics. 2011 May 6;12:213. doi: 10.1186/1471-2164-12-213.

17.

Inhibition of SREBP1 sensitizes cells to death ligands.

Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, Moffat J, Wrana JL, Schimmer AD.

Oncotarget. 2011 Mar;2(3):186-96.

18.

SATB2 augments ΔNp63α in head and neck squamous cell carcinoma.

Chung J, Lau J, Cheng LS, Grant RI, Robinson F, Ketela T, Reis PP, Roche O, Kamel-Reid S, Moffat J, Ohh M, Perez-Ordonez B, Kaplan DR, Irwin MS.

EMBO Rep. 2010 Oct;11(10):777-83. doi: 10.1038/embor.2010.125. Epub 2010 Sep 10.

19.

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma.

Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD.

Blood. 2010 Mar 18;115(11):2251-9. doi: 10.1182/blood-2009-07-231191. Epub 2010 Jan 14.

20.

Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.

Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD.

Mol Cancer Ther. 2010 Jan;9(1):246-56. doi: 10.1158/1535-7163.MCT-09-0495. Epub 2010 Jan 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk